Introduction Management of central nervous system (CNS) metastases in patients with driver-
mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and …

Introduction Brain metastases in EGFR/ALK-driven NSCLC frequently pose treatment
dilemmas. Tyrosine kinase inhibitors (TKIs) can control extracranial disease, but …

Non-small-cell lung cancer (NSCLC) ranks as a leading cause of cancer-related death
globally. Brain metastases are a frequent complication of NSCLC, with 25-40% of patients …

Brain metastases (BMs) will develop in a large proportion of patients with NSCLC
throughout the course of their disease. Among patients with NSCLC with oncogenic drivers …

Background and purpose To analyze outcomes of non-small cell lung cancer (NSCLC)
patients with brain metastases harboring EGFR or ALK mutations and examine for …

Introduction Whether EGFR tyrosine kinase inhibitors (TKIs) plus whole brain radiation
therapy (WBRT) provide a better survival benefit than EGFR TKIs alone remains …

Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …

Central nervous system (CNS) metastases, including brain metastases (BM) and
leptomeningeal metastases (LM) represent a frequent complication of non-small cell lung …

Background We investigated effects of genetic alterations in epidermal growth factor
receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral …

Lung cancer represents the most common cause of brain dissemination. Oncogene-
addicted (EGFR-and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized …